Nicotine: 4 agencies, 2006–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 18.8 years separate the first record, 31 May 2006 at HAS (France), from the most recent, 12 Mar 2025 at HAS (France).
PHARMAC (New Zealand) changed its position: not recommended on 8 Nov 2012, recommended by 9 May 2013, after a resubmission.
No assessment is on file from SMC (Scotland), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 2 of 46 records date from 2023 or later.
3 distinct indication wordings are recorded for nicotine by the agencies that label one in English (AWMSG and PBAC).
3 of these 46 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess nicotine, on 31 May 2006; PBAC (Australia) did not open a file until 2017 — an unusually long tail of 11.2 years between the earliest and latest system to look at it.
The record arrives in waves: 10 separate years each carry two or more decisions, spread across 18 years in total.
4 of the 4 agencies here assessed nicotine more than once, HAS (France) most often at 38 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed nicotine.
The full ledger for nicotine reads 41 recommended, 2 not assessed, 2 not recommended and 1 deferred.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 12 Mar 2025 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| HAS (France) | 19 Apr 2023 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| PBAC (Australia) | 2017 | Nicotine dependence | The PBAC deferred making a recommendation on whether nicotine gum and lozenges should be l… | source |
| AWMSG (Wales) | 17 Mar 2016 | To relieve and/or prevent craving and nicotine withdrawal symptoms associated with tobacco dependence. It is indicated t… | outside AWMSG criteria | source |
| PHARMAC (New Zealand) | 8 Nov 2012 | Hospital listing | PTAC advice: Not recommended for inclusion (HML) · decision reached | source |
41 further decisions for nicotine, across 4 agencies, are not shown here. They link to 25 further source documents.
Related molecules
- buprenorphine — same ATC class N07B — Other nervous system
- buprenorphine / naloxone — same ATC class N07B — Other nervous system
- varenicline — same ATC class N07B — Other nervous system
- nalmefene — same ATC class N07B — Other nervous system
- naltrexone — same ATC class N07B — Other nervous system
- vosoritide — also decided by HAS in 2025Q1
Coverage: 46 decisions for nicotine from 4 agencies, 2006 to 2025. Data to 7 Sep 2026. ATC class N07B — Other nervous system. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.